SCHEMBL7201576

SCHEMBL7201576

COc1ccc(-c2cc3cc(OC)cc(C)c3c3ccc(C#N)cc23)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPKAPK2 P49137 1/20 0.38
MAPK14 Q16539 1/20 0.38
MAPT P10636 3/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
RXFP1 Q9HBX9 1/20 0.38
CYP3A4 P08684 1/20 0.37
ALOX15 P16050 1/20 0.37
CNR1 P21554 1/20 0.37
CASP1 P29466 1/20 0.37
CNR2 P34972 1/20 0.37
CASP7 P55210 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PDE5A O76074 1/20 0.37
KDM1A O60341 1/20 0.37
TDP2 O95551 1/20 0.37
SQOR Q9Y6N5 1/20 0.37
STAT3 P40763 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7201989 0.83 MAPT (0.43) MAPKAPK2MAPTKDM4EALDH1A1HPGD
SCHEMBL7205812 0.77 ESR2 (0.55) MAPTKDM4EALDH1A1HPGDCYP3A4
SCHEMBL13251070 0.76 MAPKAPK2 (0.49) MAPKAPK2MAPTKDM4EALDH1A1HPGD
SCHEMBL13272516 0.76 MAPKAPK2 (0.49) MAPKAPK2MAPTKDM4EALDH1A1HPGD
SCHEMBL7205506 0.74 ESR1 (0.57) KDM4EALDH1A1HPGDRXFP1SMN1; SMN2
SCHEMBL7229011 0.74 HRH2 (0.47) MAPKAPK2MAPK14MAPTKDM4EALDH1A1
SCHEMBL15823025 0.71 CYP1A1 (0.51) MAPKAPK2MAPTCYP3A4ALOX15CNR1
SCHEMBL30966882 0.69 RAB9A (0.41) MAPKAPK2MAPTKDM4EALDH1A1HPGD
SCHEMBL13408700 0.69 ACACA (0.59) MAPTKDM4EALDH1A1HPGDNPSR1
SCHEMBL13098025 0.68 CYP11B1 (0.51) KDM4ECYP11B1CYP11B2AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6599921-B2 Antiproliferative agents against estrogen-dependent cancer cells dibenzothiopyran, dibenzopyran and phenanthrene derivatives NANODESIGN, INC. (CA) 2003-07-29 US disclosed
US-20020156077-A1 Non-steroidal estrogen receptor ligands PALOMA PHARMACEUTICALS, INC. 2002-10-24 US disclosed
WO-2002066428-A2 NON-STEROIDAL ESTROGEN RECEPTOR LIGANDS NANODESIGN INC. (CA) 2002-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156077-A1 Non-steroidal estrogen receptor ligands ESRRA, ESRRB, ESRRG MAPKAPK2 3933/4885MAPK14 2204/4885MAPT 4642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.